Earlier in the week, in a bid to boost industrial growth, Medicines Discovery Catapult announced the formation of a partnership with UK contract research organizations (CROs) leveraging the UK’s renowned contract research sector.
As per reports, this partnership is one amongst the 22 which have been announced by Medicines Discovery Catapult with UK CROs.
A majority of the big players in the medical industry have begun adopting revolutionary blockchain technology. Providing further proof that the underlying potential of blockchain technology is being recognized all across the globe. It is really important to keep up with such geeky information on a daily basis especially as the demand for innovative technologies is on the rise.
Sources close to the matter claim that the main aim through these partnerships is to boost international competitiveness and UK life sciences research and development (R&D) by channeling high-quality projects through best-in-class service providers.
These world-class CROs will now get added along with Medicines Discovery Catapult’s Virtual R&D Discovery Services platform. This combines full-service expert labs providing medicines drug discovery services, discovery expertise, and state-of-the-art assays, along with full service and specialist private sector CROs.
Furthermore, reports also suggest that through access to new customers and deeper market penetration the CROs in the platform will be eligible to receive added benefits.
Provided that the companies have diligence on their portfolios, assessing and maximizing their value to the industry, Virtual R&D is said to be assisting start-ups, spin-outs, perform experimental, university technology transfer offices (TTO’s) and UK-based Venture Capitalists.
Reports suggest that regardless of location, Virtual R&D is a fully scalable platform that can be applied anywhere through its wealth of service providers and world-class experts, the UK is well positioned to deliver drug discovery services for international partners, helping them to efficiently manage their portfolios and projects.
As per reports, Medicines Discovery Catapult’s Virtual R&D platform is a part of UK’s Life Sciences Industrial Strategy that emphasizes on increasing the pace of economic growth and maintaining the UK’s strength in this sector.
Speaking on the announcement, Dr. Peter Simpson, Chief Scientific Officer of Medicines Discovery Catapult, said: “Our aim is to support SMEs and academia to deliver their own discovery projects through convenient access to excellent assays and specialist drug discovery services. UK-based CROs can meet a wide range of needs for drug discovery innovators, and we are delighted to work in partnership with them to provide advice and project management to help ensure these relationships are successful.”
“The UK’s drug discovery ecosystem is rich in size and scope and CROs are a vital part of this economy. Working with Innovate UK, Medicines Discovery Catapult is playing a crucial role in supporting this sector. Bringing together academia, SMEs and CROs will drive drug discovery with benefits for society and the economy,” according to Dr. Kath Mackay, Director- Ageing Society, Health & Nutrition, Innovate UK.
